Sorafenib paradoxically activates the RAS/RAF/ERK pathway in polyclonal human NK cells during expansion and thereby enhances effector functions in a dose ‐ and time‐dependent manner

Clinical&Experimental Immunology, EarlyView.

Source: Clinical and Experimental Immunology - May 7, 2018 Category: Allergy & Immunology Authors: J.Lohmeyer , T.Nerreter , J.Dotterweich , H.Einsele , R.Seggewiss ‐Bernhardt Source Type: research